Literature DB >> 22286876

The HIVdb system for HIV-1 genotypic resistance interpretation.

Michele W Tang1, Tommy F Liu, Robert W Shafer.   

Abstract

The Stanford HIV Drug Resistance Database hosts a freely available online genotypic resistance interpretation system called HIVdb to help clinicians and laboratories interpret HIV-1 genotypic resistance tests. These tests are designed to assess susceptibility to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTI and NNRTI), protease inhibitors and integrase inhibitors. The HIVdb genotypic resistance interpretation system output consists of (1) a list of penalty scores for each antiretroviral (ARV) resistance mutation in a submitted sequence, (2) estimates of decreased NRTI, NNRTI, protease and integrase inhibitor susceptibility, and (3) comments about each ARV resistance mutation in the submitted sequence. The application's strengths are its convenience for submitting sequences, its quality control analysis, its transparency and its extensive comments. The Sierra Web service is an extension that enables laboratories analyzing many sequences to individualize the format of their results. The algorithm specification interface compiler makes it possible for HIVdb to provide results using a variety of different HIV-1 genotypic resistance interpretation algorithms.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286876      PMCID: PMC7068798          DOI: 10.1159/000331998

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  13 in total

1.  A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

Authors:  Kristel Van Laethem; Andrea De Luca; Andrea Antinori; Antonella Cingolani; Carlo Federico Perna; Anne-Mieke Vandamme
Journal:  Antivir Ther       Date:  2002-06

2.  An automated genotyping system for analysis of HIV-1 and other microbial sequences.

Authors:  Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme
Journal:  Bioinformatics       Date:  2005-08-02       Impact factor: 6.937

3.  HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes.

Authors:  Soo-Yon Rhee; Rami Kantor; David A Katzenstein; Ricardo Camacho; Lynn Morris; Sunee Sirivichayakul; Louise Jorgensen; Luis F Brigido; Jonathan M Schapiro; Robert W Shafer
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

4.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

5.  Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation.

Authors:  Bradley J Betts; Robert W Shafer
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

6.  Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.

Authors:  Jonathan M Schapiro; Joseph Scherer; Charles A Boucher; John D Baxter; Clemens Tilke; Carlo F Perno; Franco Maggiolo; Maria M Santoro; David B Hall
Journal:  Antivir Ther       Date:  2010

7.  Resistance profile of darunavir: combined 24-week results from the POWER trials.

Authors:  Sandra de Meyer; Tony Vangeneugden; Ben van Baelen; Els de Paepe; Herwig van Marck; Gaston Picchio; Eric Lefebvre; Marie-Pierre de Béthune
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

8.  Predictive value of HIV-1 genotypic resistance test interpretation algorithms.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Tommy F Liu; Natalia M Marlowe; Charles M Rowland; Richard A Rode; Anne-Mieke Vandamme; Kristel Van Laethem; Françoise Brun-Vezinet; Vincent Calvez; Jonathan Taylor; Leo Hurley; Michael Horberg; Robert W Shafer
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

9.  Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance.

Authors:  Andre Altmann; Niko Beerenwinkel; Tobias Sing; Igor Savenkov; Martin Doumer; Rolf Kaiser; Soo-Yon Rhee; W Jeffrey Fessel; Robert W Shafer; Thomas Lengauer
Journal:  Antivir Ther       Date:  2007

10.  A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences.

Authors:  Luiz Carlos Junior Alcantara; Sharon Cassol; Pieter Libin; Koen Deforche; Oliver G Pybus; Marc Van Ranst; Bernardo Galvão-Castro; Anne-Mieke Vandamme; Tulio de Oliveira
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

View more
  50 in total

1.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

2.  Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Authors:  Jonathan Z Li; Sebastien Gallien; Tri D Do; Jeffrey N Martin; Steven Deeks; Daniel R Kuritzkes; Hiroyu Hatano
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.

Authors:  Maile Y Karris; Yu-ting Kao; Derek Patel; Matthew Dawson; Steven P Woods; Florin Vaida; Celsa Spina; Douglas Richman; Susan Little; Davey M Smith
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

Review 4.  Decoding HIV resistance: from genotype to therapy.

Authors:  Irene T Weber; Robert W Harrison
Journal:  Future Med Chem       Date:  2017-08-09       Impact factor: 3.808

5.  Detection of Viruses in Clinical Samples by Use of Metagenomic Sequencing and Targeted Sequence Capture.

Authors:  Kristine M Wylie; Todd N Wylie; Richard Buller; Brandi Herter; Maria T Cannella; Gregory A Storch
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

6.  A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

Authors:  Anna N Kolomeets; Vici Varghese; Philippe Lemey; Marina R Bobkova; Robert W Shafer
Journal:  AIDS       Date:  2014-11-13       Impact factor: 4.177

7.  Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Authors:  Kerri J Penrose; Carole L Wallis; Chanson J Brumme; Kristen A Hamanishi; Kelley C Gordon; Raquel V Viana; P Richard Harrigan; John W Mellors; Urvi M Parikh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 8.  Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.

Authors:  Richard J Lessells; Ava Avalos; Tulio de Oliveira
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

9.  Bringing it all together: big data and HIV research.

Authors:  Frederic D Bushman; Spencer Barton; Aubrey Bailey; Caitlin Greig; Nirav Malani; Sourav Bandyopadhyay; John Young; Sumit Chanda; Nevan Krogan
Journal:  AIDS       Date:  2013-03-13       Impact factor: 4.177

10.  Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.

Authors:  Dana S Clutter; Shuntai Zhou; Vici Varghese; Soo-Yon Rhee; Benjamin A Pinsky; W Jeffrey Fessel; Daniel B Klein; Ean Spielvogel; Susan P Holmes; Leo B Hurley; Michael J Silverberg; Ronald Swanstrom; Robert W Shafer
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.